D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: A subanalysis of the randomized controlled MAGELLAN trial

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 4, 2014, Pages 479-487

  Cohen, A T ^a   Spiro, T E ^b   Spyropoulos, A C ^c   Desanctis, Y H ^b   Homering, M ^d   Buller H R ^e   Haskell, L ^f   Hu, D ^g   Hull, R ^h   Mebazaa, A ⁱ   Merli, G ^j   Schellong, S ^k   Tapson, V F ^l   Burton, P ^f  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Bayer Healthcare Inc   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d BAYER PHARMA AG   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^h FOOTHILLS HOSPITAL   (Canada)

ⁱ Saint Louis Lariboisière University Hospitals   (France)

^j THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^k ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

D dimer; Enoxaparin; Hospitalization; Rivaroxaban; Venous thromboembolism

Indexed keywords

D DIMER; ENOXAPARIN; PLACEBO; RIVAROXABAN; ANTICOAGULANT AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROUPS BY AGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; BLOOD; CLINICAL TRIAL; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTICOAGULANTS; ENOXAPARIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MULTIVARIATE ANALYSIS; RISK FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84898047531     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12515     Document Type: Article

References (21)

1. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AGG. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94: 750-9.
2. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
3. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V. MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513-23.
4. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD, for the EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153: 8-18.
5. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-77.
6. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31: 407-16.
7. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113: 2878-87.
8. Desjardins L, Bara L, Boutitie F, Samama MM, Cohen AT, Combe S, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 2004; 128: 519-26.
9. Fan J, Li X, Cheng Y, Yao C, Zhong N. Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China. Clin Invest Med 2011; 34: E96-104.
10. Courtney DM, Steinberg JM, McCormick JC. Prospective diagnostic accuracy assessment of the HemosIL HS D-dimer to exclude pulmonary embolism in emergency department patients. Thromb Res 2010; 125: 79-83.
11. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-14.
12. Medrano Ortega FJ, Navarro Puerto A, Vidal Serrano S, Alonso Ortiz del Río C, Gutiérrez Tous R, Marín León I. Guía de práctica clínica basada en la evidencia sobre prevención de enfermedad tromboembólica venosa en patología médica. 2007. http://www.a14.san.gva.es/cas/hospital/sesclin/PRETEMED%20140509.pdf. Accessed 12 September 2013.
13. Gallardo Jimenéz P, Guijarro Merino R, Vallejo Herrera V, Sánchez Morales D, Villalobos Sánchez A, Perelló González-Moreno JI, Gómez-Huelgas R. Assessment of venous thromboembolism risk in hospitalized medical patients. Concordance between PRETEMED guide and the recommendations of the VIII conference of the American College of Chest Physicians. Med Clin (Barc) 2012; 139: 467-72.
14. Cohen AT, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost 2012; 107: 1035-43.
15. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-9.
16. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97: 1158-64.
17. Di Nisio M, Squizzato A, Rutjes AW, Büller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 2007; 5: 296-304.
18. Ghanima W, Abdelnoor M, Mowinckel MC, Sandset PM. The performance of STA-Liatest D-dimer assay in out-patients with suspected pulmonary embolism. Br J Haematol 2006; 132: 210-5.
19. Lehman CM, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol 2004; 122: 178-84.
20. Waser G, Kathriner S, Wuillemin WA. Performance of the automated and rapid STA Liatest D-dimer on the STA-R analyzer. Thromb Res 2005; 116: 165-70.
21. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-36.